MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types-Reference-Cited by-同舟云学术

MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types

Published:2018-10 Issue: Volume:29 Page:viii439-viii440
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Chau I.,Haag G.M.,Rahma O.E.,Macarulla T.M.,McCune S.L.,Yardley D.A.,Solomon B.J.,Johnson M.,Vidal G.A.,Schmid P.,Argiles G.,Dimick K.,Mahrus S.,Abdullah H.,He X.,Sayyed P.,Barak H.,Bleul C.,Cha E.,Drakaki A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/29/suppl_8/mdy288.110/26138262/mdy288.110.pdf

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current Status and Future Perspectives of Antibody–Drug Conjugates in Hormone Receptor-Positive Breast Cancer;Cancers;2024-05-08

2. Considerations for master protocols using external controls;Journal of Biopharmaceutical Statistics;2024-02-16

3. Evaluating hybrid controls methodology in early‐phase oncology trials: A simulation study based on the MORPHEUS‐UC trial;Pharmaceutical Statistics;2023-09-24

4. Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma);Clinical Cancer Research;2023-08-31

5. Borrowing Concurrent Information from Non-Concurrent Control to Enhance Statistical Efficiency in Platform Trials;Current Oncology;2023-03-31